Literature DB >> 8902391

The new vaccines: building viruses that elicit antitumor immunity.

N P Restifo1.   

Abstract

Whereas cancer cells are poor immunogens, some viruses are capable of eliciting powerful and lifelong immunity. Recombinant viruses and plasmid DNA encoding tumor-associated antigens can elicit powerful and specific immune responses that can be enhanced by the use of cytokines and costimulatory molecules. These immune responses have destroyed growing tumor cells in experimental animal models. For the first time, immunotherapeutic strategies that employ recombinant viruses are being tested in clinical trials with cancer patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8902391      PMCID: PMC1950785          DOI: 10.1016/s0952-7915(96)80082-3

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  52 in total

1.  Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.

Authors:  Y Zhai; J C Yang; P Spiess; M I Nishimura; W W Overwijk; B Roberts; N P Restifo; S A Rosenberg
Journal:  J Immunother       Date:  1997-01       Impact factor: 4.456

2.  Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.

Authors:  M Wang; P W Chen; V Bronte; S A Rosenberg; N P Restifo
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1995-10

3.  Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.

Authors:  R S Chamberlain; M W Carroll; V Bronte; P Hwu; S Warren; J C Yang; M Nishimura; B Moss; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

4.  CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma.

Authors:  O Mandelboim; G Berke; M Fridkin; M Feldman; M Eisenstein; L Eisenbach
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

5.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.

Authors:  S A Rosenberg; D E White
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-01

6.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

Review 7.  Mutant ras epitopes as targets for cancer vaccines.

Authors:  S I Abrams; P H Hand; K Y Tsang; J Schlom
Journal:  Semin Oncol       Date:  1996-02       Impact factor: 4.929

8.  Identification of human cancers deficient in antigen processing.

Authors:  N P Restifo; F Esquivel; Y Kawakami; J W Yewdell; J J Mulé; S A Rosenberg; J R Bennink
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

9.  The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.

Authors:  A Y Huang; P H Gulden; A S Woods; M C Thomas; C D Tong; W Wang; V H Engelhard; G Pasternack; R Cotter; D Hunt; D M Pardoll; E M Jaffee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.

Authors:  J B Rao; R S Chamberlain; V Bronte; M W Carroll; K R Irvine; B Moss; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

View more
  13 in total

Review 1.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

2.  Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.

Authors:  D R Surman; M E Dudley; W W Overwijk; N P Restifo
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

3.  Cancer therapy using a self-replicating RNA vaccine.

Authors:  H Ying; T Z Zaks; R F Wang; K R Irvine; U S Kammula; F M Marincola; W W Leitner; N P Restifo
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

4.  Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases.

Authors:  A McAllister; A E Arbetman; S Mandl; C Peña-Rossi; R Andino
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 5.  The promise of nucleic acid vaccines.

Authors:  N P Restifo; H Ying; L Hwang; W W Leitner
Journal:  Gene Ther       Date:  2000-01       Impact factor: 5.250

6.  Creating therapeutic cancer vaccines: notes from the battlefield.

Authors:  W W Overwijk; N P Restifo
Journal:  Trends Immunol       Date:  2001-01       Impact factor: 16.687

7.  Immunochemical termination of self-tolerance.

Authors:  Jan Grünewald; Meng-Lin Tsao; Roshan Perera; Liqun Dong; Frank Niessen; Ben G Wen; Diane M Kubitz; Vaughn V Smider; Wolfram Ruf; Marc Nasoff; Richard A Lerner; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-06       Impact factor: 11.205

8.  Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer.

Authors:  N P Restifo; D R Surman; H Zheng; P Palese; S A Rosenberg; A García-Sastre
Journal:  Virology       Date:  1998-09-15       Impact factor: 3.616

Review 9.  Developing recombinant and synthetic vaccines for the treatment of melanoma.

Authors:  N P Restifo; S A Rosenberg
Journal:  Curr Opin Oncol       Date:  1999-01       Impact factor: 3.645

10.  Influence of tumors on protective anti-tumor immunity and the effects of irradiation.

Authors:  Gemma A Foulds; Jürgen Radons; Mira Kreuzer; Gabriele Multhoff; Alan G Pockley
Journal:  Front Oncol       Date:  2013-02-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.